Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality

Amneal Pharmaceuticals (AMRX) has closed out FY 2025 with fourth quarter revenue of US$814.3 million and basic EPS of US$0.11, alongside trailing twelve month revenue of about US$3.0 billion and basic EPS of US$0.23. Over recent periods the company has seen quarterly revenue move from US$702.5 million in Q3 FY 2024 to US$730.5 million in Q4 FY 2024 and then to US$695.4 million, US$724.5 million, US$784.5 million and US$814.3 million across the four quarters of FY 2025. Basic EPS shifted from a loss of US$0.10 in Q4 FY 2024 to positive readings of US$0.04, US$0.07, US$0.01 and US$0.11 through FY 2025, which may prompt investors to focus on how sustainable these margins look after a year that included one off charges and tighter interest coverage.

See our full analysis for Amneal Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely followed stories about Amneal Pharmaceuticals, and where the fresh data challenges or supports those narratives.

See what the community is saying about Amneal Pharmaceuticals

Profit swings to US$72.1m over the year

• On a trailing twelve month basis, net income moved from a loss of US$116.9 million in Q4 FY 2024 to profit of US$72.1 million by Q4 FY 2025, alongside revenue of about US$3.0 billion and basic EPS of US$0.23.
• Analysts' consensus view links this move into profit with expectations for wider margins over time. However, the presence of a US$58.0 million one off loss in the last 12 months means reported earnings quality is mixed, and investors need to separate recurring profit from these less frequent items.

High P/E of 60.7x vs US peers

• The stock is trading on a trailing P/E of 60.7x compared with 16.7x for the US Pharmaceuticals industry and 44.6x for peers, even though trailing twelve month net income is US$72.1 million on roughly US$3.0 billion of revenue.
• Bears focus on this premium multiple and argue that high debt and weak interest coverage increase financial risk, especially when a large one off loss has affected recent earnings. They therefore see the rich P/E and leverage as reasons for caution despite the move back into profit.

DCF fair value far above US$13.72 price

• The supplied DCF fair value of US$48.62 sits well above the current share price of US$13.72 and the average analyst target of US$17.00, all against trailing twelve month profit of US$72.1 million.
• Supporters of the bullish view point to this large gap to DCF fair value and to forecasts for about 48.9% yearly earnings growth. At the same time, the need for better interest coverage and the impact of one off items in the last 12 months means the latest profit run rate still has to show it can back up those optimistic assumptions.

On these numbers, bulls and bears are reading the same profit rebound in very different ways. It can help to compare this print against a fuller bullish thesis before deciding how much weight to give the DCF gap and growth forecasts.🐂 Amneal Pharmaceuticals Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Amneal Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards on the table, the picture is clearly mixed. Act quickly to review the underlying data and weigh the 4 key rewards and 2 important warning signs

Explore Alternatives

Amneal Pharmaceuticals is carrying a rich P/E against US peers while juggling high debt, weak interest coverage, and earnings that still include sizeable one off items.

If you are wary of that combination of premium pricing and balance sheet pressure, it is worth checking stocks in the 72 resilient stocks with low risk scores right now for potentially steadier ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com